Difficulty: Medium
Average Score: 62%
Practice
A patient with a 30-year history of type 1 diabetes comes to you with a complaint of bloating and sour belching after meals. On several occasions, vomiting has occurred after a meal. Evaluation reveals delayed emptying of the stomach, and you diagnose diabetic gastroparesis. Which of the following drugs would be most useful in this patient?
Correct answer
B
Rationale
In this case, the most appropriate drug for the patient with diabetic gastroparesis is option B, Metoclopramide. Metoclopramide is a prokinetic agent that works by enhancing gastrointestinal motility, which can help in improving gastric emptying. This is crucial for patients with gastroparesis as it can alleviate symptoms like bloating, belching, and vomiting after meals.
Option A, Famotidine, is a histamine H2-receptor antagonist commonly used to reduce stomach acid production and treat conditions like ulcers and acid reflux. However, it does not address the underlying issue of delayed gastric emptying seen in gastroparesis.
Option C, Misoprostol, is a synthetic prostaglandin E1 analog used to prevent gastric ulcers in patients taking NSAIDs. It does not have a direct effect on gastric motility and would not be the first-line treatment for gastroparesis.
Option D, Omeprazole, is a proton pump inhibitor that reduces stomach acid production and is primarily used to treat conditions like GERD and ulcers. While it can help with acid-related symptoms, it does not address the motility issues seen in gastroparesis.
Educationally, understanding the mechanism of action of each drug is essential in choosing the correct treatment for a specific condition. In the context of diabetic gastroparesis, selecting a prokinetic agent like Metoclopramide makes sense to target the delayed gastric emptying, thereby improving the patient's symptoms and quality of life.
Option A, Famotidine, is a histamine H2-receptor antagonist commonly used to reduce stomach acid production and treat conditions like ulcers and acid reflux. However, it does not address the underlying issue of delayed gastric emptying seen in gastroparesis.
Option C, Misoprostol, is a synthetic prostaglandin E1 analog used to prevent gastric ulcers in patients taking NSAIDs. It does not have a direct effect on gastric motility and would not be the first-line treatment for gastroparesis.
Option D, Omeprazole, is a proton pump inhibitor that reduces stomach acid production and is primarily used to treat conditions like GERD and ulcers. While it can help with acid-related symptoms, it does not address the motility issues seen in gastroparesis.
Educationally, understanding the mechanism of action of each drug is essential in choosing the correct treatment for a specific condition. In the context of diabetic gastroparesis, selecting a prokinetic agent like Metoclopramide makes sense to target the delayed gastric emptying, thereby improving the patient's symptoms and quality of life.